Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

You may be eligible if

• DISEASE CHARACTERISTICS:
• One of the following histologically or cytologically confirmed diseases:
• * Indolent B-cell non-Hodgkin's lymphoma (NHL)
• * Stage II-IV disease
• * Chronic lymphocytic leukemia (CLL) meeting 1 of the following risk criteria:
• * Intermediate-risk with progressive disease
• * High-risk, modified Rai stage disease
• CD20-positive by flow cytometry or immunohistochemistry
• Measurable disease
• Rituximab-refractory disease, defined as failure to achieve a response to the last course of prior treatment with rituximab alone or in combination with other therapeutic modalities
• No known neoplastic leptomeningeal involvement and/or brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2 OR
• Karnofsky 60-100%
• Life expectancy
• More than 3 months
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 50,000/mm\^3
• WBC ≥ 3,000/mm\^3
• Hepatic
• AST and ALT ≤ 2.5 times upper limit of normal
• Bilirubin normal (unless due to Gilbert's disease or organ involvement by NHL or CLL)
• Renal
• Creatinine normal OR
• Creatinine clearance ≥ 60 mL/min
• Cardiovascular
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No history of anaphylaxis or immunoglobulin (Ig) E-mediated hypersensitivity to murine protein
• * Prior infusion reactions to rituximab without an IgE component allowed
• No active or ongoing infection
• No psychiatric illness or social situation that would preclude study compliance
• No other uncontrolled illness
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• See Radiotherapy
• At least 12 weeks since prior rituximab
• More than 4 weeks since prior immunotherapy and recovered
• Chemotherapy
• No more than 3 prior chemotherapy regimens
• More than 4 weeks since prior chemotherapy and recovered
• Endocrine therapy
• No concurrent glucocorticoids
• Radiotherapy
• At least 12 weeks since prior radioimmunotherapy
• More than 4 weeks since prior radiotherapy and recovered
• Surgery
• Not specified
• Other
• At least 4 weeks since prior therapy for the malignancy
• No other concurrent anticancer therapy
• No other concurrent investigational agents